Accueil   Diary - News   All news Adocia Initiates a Phase 1/2 Clinical Trial

Adocia Initiates a Phase 1/2 Clinical Trial

Adocia Initiates a Phase 1/2 Clinical Trial on the Post-Meal Effect of Rapid-Acting Human Insulin, HinsBet® U100

 

 

Adocia, announced today the initiation of a Phase 1b clinical trial to evaluate the post meal effects of HinsBet U100 in subjects with type 1 diabetes. HinsBet is a rapid-acting formulation of recombinant human insulin using Adocia’s proprietary technology BioChaperone, which is designed to accelerate insulin absorption. Another application of this technology, to accelerate insulin analogs such as insulin lispro, was licensed to Eli Lilly in December 2014. BioChaperone Lispro has shown an ultra-rapid profile, relative to Humalog® (insulin lispro, Lilly), in four Phase 1/2 clinical studies.

 

 

Read the press release

 

 

By continuing your navigation on our site, you accept the use of cookies and the collection of your data and personal information by Lyonbiopôle, for the purposes of measuring the traffic on the website, to provide statistics and to offer you adapted content to your centers of interest. To exercise your rights of access, rectification, opposition, deletion and portability, in accordance with the General Data Protection Regulation (EU 2016/679), you are informed that you can send your request to dpo@lyonbiopole.com. More details are available by clicking here I agree